Andrew F Kolodziej Ph.D.
Vice President, Flatley Discovery Lab
Andrew Kolodziej received his Ph.D. in Chemistry from Massachusetts Institute of Technology in 1991 and completed postdoctoral training in Professor Daniel Koshland's lab at University of California, Berkeley. He joined EPIX Pharmaceuticals in 1996, where he discovered and developed molecular imaging probes to enhance MRI guided diagnosis of cardiovascular disease, and assumed various roles in directing preclinical drug discovery. In 2007, Dr. Kolodziej assumed the role of project leader for a 2 year collaboration with the Cystic Fibrosis Foundation focused on the discovery and optimization of correctors of deltaF508-CFTR, including the first reported dual-acting corrector-potentiator. In 2011, he joined the Flatley Discovery Lab as Vice President of Research where he directs discovery and optimization of deltaF508-CFTR modulators as part of a multidisciplinary team of 25 scientists. He is a co-inventor on 12 patents and co-author of 16 scientific articles and book chapters.